tag:blogs.poz.com,2009-03-02:/tim//43 2013-12-18T17:26:26Z HIV Project Director, Treatment Action Group (TAG) Movable Type 4.34-en tag:blogs.poz.com,2013:/tim//43.400673 2013-12-17T17:11:14Z 2013-12-18T17:26:26Z

A young HIV-positive man dies after being denied access to a lung transplant program in New York City, resulting in activism demanding a prompt reversal of policies that fly in the face of science that bodes well for people living with HIV in desperate need of donated organs.

Tim Horn http://blogs.poz.com/tim A young HIV-positive man dies after being denied access to a lung transplant program in New York City, resulting in activism demanding a prompt reversal of policies that fly in the face of science that bodes well for people living with HIV in desperate need of donated organs. tag:blogs.poz.com,2013:/tim//43.400630 2013-10-11T13:43:16Z 2013-10-11T15:31:20Z

It is lamentable that an event attempting to look toward a brighter future should harken back to the dark days when people with HIV and community-based activists were excluded from attending scientific meetings.

Tim Horn http://blogs.poz.com/tim It is lamentable that an event attempting to look toward a brighter future should harken back to the dark days when people with HIV and community-based activists were excluded from attending scientific meetings. tag:blogs.poz.com,2013:/tim//43.400628 2013-10-08T14:19:27Z 2013-10-08T16:53:57Z

Far too many people living with HIV in the United States--and elsewhere around the world--aren't accessing the care they need to benefit from the personal and public health benefits of antiretroviral therapy.

Tim Horn http://blogs.poz.com/tim Far too many people living with HIV in the United States--and elsewhere around the world--aren't accessing the care they need to benefit from the personal and public health benefits of antiretroviral therapy. tag:blogs.poz.com,2013:/tim//43.400543 2013-06-13T20:46:39Z 2013-06-13T22:08:21Z

Gilead's experimental nucleotide reverse transcriptase inhibitor tenofovir alafenamide fumarate (TAF) is being studied as a component of next-generation fixed-dose combination tablets. It also needs to be developed as a stand-alone drug, which does not appear to be on Gilead Science's radar.

Tim Horn http://blogs.poz.com/tim Gilead's experimental nucleotide reverse transcriptase inhibitor tenofovir alafenamide fumarate (TAF) is being studied as a component of next-generation fixed-dose combination tablets. It also needs to be developed as a stand-alone drug, which does not appear to be on Gilead Science's radar. tag:blogs.poz.com,2013:/tim//43.400528 2013-06-04T16:33:51Z 2013-06-07T12:53:51Z

With the specter of AIDS having finally been chased from the near horizon, attention has turned to health problems that may lie further down the road.

Tim Horn http://blogs.poz.com/tim With the specter of AIDS having finally been chased from the near horizon, attention has turned to health problems that may lie further down the road. tag:blogs.poz.com,2013:/tim//43.400500 2013-05-09T13:14:08Z 2013-05-09T19:04:45Z

The United States is on course for some much-needed economic relief from the crippling cost of HIV treatment, with the anticipated arrival of generic versions of guidelines-preferred antiretrovirals. However, much preparation is required to maximize price competition, maintain patient choice, and ensure that savings are used to the advantage of people living with HIV.

Tim Horn http://blogs.poz.com/tim The United States is on course for some much-needed economic relief from the crippling cost of HIV treatment, with the anticipated arrival of generic versions of guidelines-preferred antiretrovirals. However, much preparation is required to maximize price competition, maintain patient choice, and ensure that savings are used to the advantage of people living with HIV. tag:blogs.poz.com,2012:/tim//43.400387 2012-12-14T17:10:05Z 2013-01-02T22:14:30Z

We have until January 4 to convince the United States Preventive Services Task Force to issue strong hepatitis C testing recommendations, in order to convince health care providers and insurers that it truly is a matter of life and death for hundreds of thousands of people unknowingly living with the life-threatening disease.

Tim Horn http://blogs.poz.com/tim We have until January 4 to convince the United States Preventive Services Task Force to issue strong hepatitis C testing recommendations, in order to convince health care providers and insurers that it truly is a matter of life and death for hundreds of thousands of people unknowingly living with the life-threatening disease. tag:blogs.poz.com,2012:/tim//43.400365 2012-11-10T19:19:23Z 2012-12-14T17:44:13Z

If we're going to make headway in terms of preventing and treating serious non-AIDS health complications among people living with HIV, which are very much on the rise and a serious risk to disease-free survival--not to mention cure the infection once and for all--we're going to need the full-on cooperation of pharmaceutical companies manufacturing drugs for other diseases that show potential for people living with HIV.

Tim Horn http://blogs.poz.com/tim If we're going to make headway in terms of preventing and treating serious non-AIDS health complications among people living with HIV, which are very much on the rise and a serious risk to disease-free survival--not to mention cure the infection once and for all--we're going to need the full-on cooperation of pharmaceutical companies manufacturing drugs for other diseases that show potential for people living with HIV. tag:blogs.poz.com,2012:/tim//43.400132 2012-05-04T16:30:03Z 2012-06-12T21:19:50Z

The national portrait of entry into and retention in HIV care has been consistently abysmal and the astounding dearth of data from well-designed studies exploring entry and retention strategies that could be used to construct well-formed recommendations is, perhaps, the final and most pressing frontier of HIV treatment advocacy in the United States.

Tim Horn http://blogs.poz.com/tim The national portrait of entry into and retention in HIV care has been consistently abysmal and the astounding dearth of data from well-designed studies exploring entry and retention strategies that could be used to construct well-formed recommendations is, perhaps, the final and most pressing frontier of HIV treatment advocacy in the United States. tag:blogs.poz.com,2011:/tim//43.32733 2011-03-29T16:50:06Z 2012-05-14T22:09:34Z

AIDS Healthcare Foundation's campaign against the FDA approval of Truvada as PrEP is misplaced. While there are numerous lingering questions regarding the efficacy, risks and accessibility of the drug as a tool in the HIV prevention chest, the PrEP genie is already out of the bottle. Community advocacy efforts are best directed at Gilead and public health agencies to ensure safe and affordable use.

Tim Horn http://blogs.poz.com/tim AIDS Healthcare Foundation's campaign against the FDA approval of Truvada as PrEP is misplaced. While there are numerous lingering questions regarding the efficacy, risks and accessibility of the drug as a tool in the HIV prevention chest, the PrEP genie is already out of the bottle. Community advocacy efforts are best directed at Gilead and public health agencies to ensure safe and affordable use. tag:blogs.poz.com,2010:/tim//43.3194 2010-12-30T20:37:18Z 2012-03-20T21:04:56Z

The second of a two-part look at the top treatment news of 2010.

Tim Horn http://blogs.poz.com/tim The second of a two-part look at the top treatment news of 2010. tag:blogs.poz.com,2010:/tim//43.3188 2010-12-27T16:31:28Z 2012-03-20T21:06:08Z

The first of a two-part look at the top treatment news of 2010.

Tim Horn http://blogs.poz.com/tim The first of a two-part look at the top treatment news of 2010. tag:blogs.poz.com,2010:/tim//43.3180 2010-12-17T17:09:50Z 2010-12-17T18:04:56Z

Scare tactics don't work, especially when the goal is to get people living with HIV who are unaware of their status tested and into care.

Tim Horn http://blogs.poz.com/tim Scare tactics don't work, especially when the goal is to get people living with HIV who are unaware of their status tested and into care. tag:blogs.poz.com,2010:/tim//43.3159 2010-11-30T14:03:24Z 2010-11-30T19:22:13Z

The international iPrEx study confirms that PrEP works, though not at the level researchers were initially hoping. The clinical trial, while encouraging, raises many more questions than answers.

Tim Horn http://blogs.poz.com/tim The international iPrEx study confirms that PrEP works, though not at the level researchers were initially hoping. The clinical trial, while encouraging, raises many more questions than answers. tag:blogs.poz.com,2010:/tim//43.3137 2010-11-12T15:30:15Z 2010-11-12T22:07:24Z

Egrifta (tesamorelin) has been approved for the treatment of HIV-associated lipodystrophy. The question is, will a possible high price tag keep it out of the hands of those who need it?

Tim Horn http://blogs.poz.com/tim Egrifta (tesamorelin) has been approved for the treatment of HIV-associated lipodystrophy. The question is, will a possible high price tag keep it out of the hands of those who need it?